ReviewCerebellum & ataxias2015
Guidelines for treatment of immune-mediated cerebellar ataxias.
Review in Cerebellum & ataxias, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Diagnostic Criteria for Primary Autoimmune Cerebellar Ataxia-Guidelines from an International Task Force on Immune-Mediated Cerebellar Ataxias.Cerebellum (London, England) · 2020Guideline
- Serum antigliadin antibodies in cerebellar ataxias: a systematic review and meta-analysis.Journal of neurology, neurosurgery, and psychiatry · 2018Pooled it
- Relapsing Seronegative Immune-Mediated Cerebellar Ataxia with Evolving Intrathecal Immune Activation and Rituximab Consolidation in a Toddler: A Case Report.Cerebellum (London, England) · 2026Article
- A Case Report of Reversible Mitochondrial Bioenergetic Dysfunction in PBMCs in Anti-GAD65-Associated Cerebellar Ataxia.Cerebellum (London, England) · 2026Article
- Effect of Aminopyridines on Oculomotor Dysfunction in Anti-GAD Ataxia: A Brief Report.Cerebellum (London, England) · 2025Article
- Progress and challenges in sporadic late-onset cerebellar ataxias.Nature reviews. Neurology · 2025Review
- Exacerbation of paraneoplastic cerebellar degeneration by immune checkpoint inhibitor use in endometrial cancer.Gynecologic oncology reports · 2025Article
- Autoimmune cerebellar ataxia with anti-Homer3 antibodies associated with herpesvirus infection: a case report and literature review.Frontiers in immunology · 2025Review
- Clinical features of autoimmune cerebellar ataxia related to neuronal antibodies.Frontiers in immunology · 2025Article
- A Case Series of Anti-Metabotropic Glutamate Receptor 2 Antibody-Related Diseases with Distinct Neurological Involvement.ImmunoTargets and therapy · 2025Article
- A candidate projective neuron type of the cerebellar cortex: the synarmotic neuron.European journal of histochemistry : EJH · 2024Review
- Consensus Paper: Latent Autoimmune Cerebellar Ataxia (LACA).Cerebellum (London, England) · 2024Article
- Autoimmune Cerebellar Ataxia: Etiology and Clinical Characteristics of a Case Series from China.Cerebellum (London, England) · 2023Review
- Ataxias: Hereditary, Acquired, and Reversible Etiologies.Seminars in neurology · 2023Article
- Advances in the Pathogenesis of Auto-antibody-Induced Cerebellar Synaptopathies.Cerebellum (London, England) · 2023Review
- Rare Etiologies in Immune-Mediated Cerebellar Ataxias: Diagnostic Challenges.Brain sciences · 2022Review
- Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses.Cerebellum (London, England) · 2022Review
- Immune-Mediated Cerebellar Ataxia Associated With Neuronal Surface Antibodies.Frontiers in immunology · 2022Article
- Cerebellar ataxia and myeloradiculopathy associated with AP3B2 antibody: a case report and literature review.Journal of neurology · 2021Review
- Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-mediated cerebellar ataxias include gluten ataxia, paraneoplastic cerebellar degeneration, GAD antibody associated cerebellar ataxia, and Hashimoto's encephalopathy. Despite the identification of an increasing number of immune-mediated cerebellar ataxias, there is no proposed standardized therapy. We evaluated the efficacies of immunotherapies in reported cases using a common scale of daily activity. The analysis highlighted the importance of removal of autoimmune triggering factors (e.g., gluten or cancer) and the need for immunotherapy evaluation (e.g., corticosteroids, intravenous immunoglobulin, immunosuppressants) and adaptation according to each subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.